Details of the Drug

General Information of Drug (ID: DM58WKG)

Drug Name

Panobinostat

Synonyms

Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Approved	[1]
Type-2 diabetes	5A11	Phase 3	[2], [3]
Primary myelofibrosis	2A20.2	Phase 2	[2], [4]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

349.4

Topological Polar Surface Area (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2 h [5]
Clearance: The drug present in the plasma can be removed from the body at the rate of 10.2 mL/min/kg [6]
Half-life: The concentration or amount of drug in body reduced by one-half in 30 hours [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.1% [6]

Chemical Identifiers

Formula: C21H23N3O2
IUPAC Name: (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
Canonical SMILES: CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO
InChI: InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+
InChIKey: FPOHNWQLNRZRFC-ZHACJKMWSA-N

Cross-matching ID

PubChem CID: 6918837
ChEBI ID: CHEBI:85990
CAS Number: 404950-80-7
DrugBank ID: DB06603
TTD ID: D0E3SH
VARIDT ID: DR00181
INTEDE ID: DR1234
ACDINA ID: D00507

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase 1 (HDAC1)	TT6R7JZ	HDAC1_HUMAN	Inhibitor	[7], [8], [9], [10]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Multiple myeloma

ICD Disease Classification

2A83

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histone deacetylase 1 (HDAC1)	DTT	HDAC1	6.27E-01	0.11	0.33
P-glycoprotein 1 (ABCB1)	DTP	P-GP	2.30E-01	3.06E-01	7.43E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	2.76E-01	-4.64E-01	-9.16E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Panobinostat (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Panobinostat caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[35]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Ivosidenib.	Acute myeloid leukaemia [2A60]	[35]
Arn-509	DMT81LZ	Major	Increased metabolism of Panobinostat caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[35]
Gilteritinib	DMWQ4MZ	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Gilteritinib.	Acute myeloid leukaemia [2A60]	[35]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Oliceridine.	Acute pain [MG31]	[35]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Panobinostat and Ivabradine.	Angina pectoris [BA40]	[36]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[35]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Panobinostat and Levalbuterol.	Asthma [CA23]	[37]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Panobinostat and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[38]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Eribulin.	Breast cancer [2C60-2C6Y]	[35]
Tucatinib	DMBESUA	Major	Decreased metabolism of Panobinostat caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[39]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Panobinostat caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[39]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Bosutinib.	Breast cancer [2C60-2C6Y]	[35]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Panobinostat and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[35]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Panobinostat and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[40]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Panobinostat and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[37]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Panobinostat and Regorafenib.	Colorectal cancer [2B91]	[41]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Panobinostat and Ardeparin.	Coronary thrombosis [BA43]	[41]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Pasireotide.	Cushing syndrome [5A70]	[35]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Osilodrostat.	Cushing syndrome [5A70]	[35]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Panobinostat caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[39]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Panobinostat caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[39]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Panobinostat and Danaparoid.	Deep vein thrombosis [BD71]	[41]
Vortioxetine	DM6F1PU	Major	Increased risk of bleeding by the combination of Panobinostat and Vortioxetine.	Depression [6A70-6A7Z]	[42]
OPC-34712	DMHG57U	Major	Decreased metabolism of Panobinostat caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[43]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Deutetrabenazine.	Dystonic disorder [8A02]	[35]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Ingrezza.	Dystonic disorder [8A02]	[35]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Panobinostat caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Panobinostat caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[35]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Panobinostat and Cannabidiol.	Epileptic encephalopathy [8A62]	[36]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Panobinostat caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[35]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Panobinostat and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[41]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Panobinostat caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[39]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Panobinostat caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Teriflunomide	DMQ2FKJ	Major	Additive myelosuppressive effects by the combination of Panobinostat and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[44]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Panobinostat and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[45]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Panobinostat caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[39]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Panobinostat caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[39]
Polyethylene glycol	DM4I1JP	Major	Increased risk of ventricular arrhythmias by the combination of Panobinostat and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[46]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Panobinostat and Denosumab.	Low bone mass disorder [FB83]	[47]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Crizotinib.	Lung cancer [2C25]	[35]
Ceritinib	DMB920Z	Major	Decreased metabolism of Panobinostat caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[39]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Panobinostat caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[35]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Osimertinib.	Lung cancer [2C25]	[35]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Lumefantrine.	Malaria [1F40-1F45]	[41]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Panobinostat and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[48]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Panobinostat and Idelalisib.	Mature B-cell leukaemia [2A82]	[49]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Panobinostat caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[39]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Panobinostat and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[41]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Panobinostat and Ibrutinib.	Mature B-cell lymphoma [2A85]	[41]
Arry-162	DM1P6FR	Major	Increased risk of bleeding by the combination of Panobinostat and Arry-162.	Melanoma [2C30]	[41]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Vemurafenib.	Melanoma [2C30]	[50]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Panobinostat and LGX818.	Melanoma [2C30]	[35]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Panobinostat caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[35]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Panobinostat and Tecfidera.	Multiple sclerosis [8A40]	[51]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Panobinostat and Siponimod.	Multiple sclerosis [8A40]	[41]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Panobinostat and Fingolimod.	Multiple sclerosis [8A40]	[52]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Panobinostat and Ocrelizumab.	Multiple sclerosis [8A40]	[53]
Ozanimod	DMT6AM2	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Ozanimod.	Multiple sclerosis [8A40]	[35]
Fedratinib	DM4ZBK6	Major	Increased risk of bleeding by the combination of Panobinostat and Fedratinib.	Myeloproliferative neoplasm [2A20]	[41]
Ruxolitinib	DM7Q98D	Major	Increased risk of bleeding by the combination of Panobinostat and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[41]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Entrectinib.	Non-small cell lung cancer [2C25]	[35]
Nepafenac	DMYK490	Moderate	Increased risk of bleeding by the combination of Panobinostat and Nepafenac.	Osteoarthritis [FA00-FA05]	[54]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Rucaparib.	Ovarian cancer [2C73]	[35]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Triclabendazole.	Parasitic worm infestation [1F90]	[35]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Panobinostat caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[55]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[56]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Lefamulin.	Pneumonia [CA40]	[35]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Degarelix.	Prostate cancer [2C82]	[35]
Enzalutamide	DMGL19D	Major	Increased metabolism of Panobinostat caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[35]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Relugolix.	Prostate cancer [2C82]	[35]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Panobinostat and Golimumab.	Rheumatoid arthritis [FA20]	[57]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Panobinostat when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[58]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Panobinostat caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[39]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Panobinostat caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[36]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Panobinostat caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[39]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Panobinostat and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[35]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[35]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Pitolisant.	Somnolence [MG42]	[35]
Plicamycin	DM7C8YV	Major	Increased risk of bleeding by the combination of Panobinostat and Plicamycin.	Testicular cancer [2C80]	[41]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Panobinostat caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[59]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Panobinostat and Apixaban.	Thrombosis [DB61-GB90]	[41]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Panobinostat caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[39]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Lenvatinib.	Thyroid cancer [2D10]	[35]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Panobinostat and Cabozantinib.	Thyroid cancer [2D10]	[35]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Panobinostat caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[35]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Panobinostat and Betrixaban.	Venous thromboembolism [BD72]	[41]
-----------


⏷ Show the Full List of 89 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 1	E00263	19700	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Gelatin	E00630	Not Available	Other agent
Magnesium stearate	E00208	11177	lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Colcothar yellow	E00436	518696	Colorant
Haematite red	E00236	14833	Colorant
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant
--------------------


⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Panobinostat 10 mg capsule	10 mg	Oral Capsule	Oral
Panobinostat 15 mg capsule	15 mg	Oral Capsule	Oral
Panobinostat 20 mg capsule	20 mg	Oral Capsule	Oral
Panobinostat Lactate eq 10mg base capsule	eq 10mg base	Capsule	Oral
Panobinostat Lactate eq 15mg base capsule	eq 15mg base	Capsule	Oral
Panobinostat Lactate eq 20mg base capsule	eq 20mg base	Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7489).
3	Progress of HDAC inhibitor panobinostat in the treatment of cancer. Curr Drug Targets. 2014 Jun;15(6):622-34.
4	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
8	Emerging drugs in cutaneous T cell lymphoma. Expert Opin Emerg Drugs. 2008 Jun;13(2):345-61.
9	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
10	Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.
11	Panobinostat for the treatment of multiple myeloma: the evidence to date. J Blood Med. 2015 Oct 8;6:269-76.
12	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert Rev Clin Pharmacol. 2016;9(1):35-48.
13	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
23	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
24	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
25	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
26	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
27	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
28	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
29	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
30	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
31	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
32	NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
33	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
34	2011 Pipeline of 4SC AG.
35	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
36	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
37	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
38	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
39	Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
40	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
41	Cerner Multum, Inc. "Australian Product Information.".
42	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
43	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
44	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
45	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
46	Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
47	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
48	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
49	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
50	Canadian Pharmacists Association.
51	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
52	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
53	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
54	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
55	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
56	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
57	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
58	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
59	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.